Vaxart, Inc. announced the appointment of Edward B. Berg as the Company's first in-house General Counsel and Senior Vice President, effective February 14, 2022. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutical Inc., where he served as VP, Deputy General Counsel since 2018.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.025 USD | +8.51% | +40.79% | +79.82% |
May. 13 | Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
May. 13 | Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.82% | 167M | |
+7.81% | 113B | |
+10.90% | 106B | |
+0.41% | 22.27B | |
-11.89% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.63% | 17.24B | |
+6.76% | 14.29B | |
+35.78% | 12.52B |
- Stock Market
- Equities
- VXRT Stock
- News Vaxart, Inc.
- Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel